Prezcobix (Darunavir/Cobicistat) for HIV

Overview
Prezcobix is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in adults in combination with other antiretroviral drugs. Prezcobix is a combination drug composed of Darunavir and Cobicistat, which are also known respectively by the abbreviations DRV and COBI. Darunavir is an antiviral medication of the protease inhibitor (PI) class. Darunavir is believed to work by preventing HIV from replicating in cells. Cobicistat is a pharmacokinetic enhancer. Cobicistat is believed to work by preventing the body from breaking down some antiretroviral drugs, increasing their effectiveness.

How do I take it?
Prescribing information states that Prezcobix is taken once daily. Prezcobix comes in tablet form.

Side effects
The FDA-approved label for Prezcobix lists common side effects including rash, headache, nausea, diarrhea, vomiting, and abdominal pain. Rare but serious side effects listed for Prezcobix include severe skin reactions and liver damage.

For more details about this treatment, visit:

Prezcobix highlights of prescribing information – Janssen

Overview of HIV Treatments – AIDS.gov